Replies to post #143566 on Biotech Values

[mcbio]

That said, I think there is about a 50% chance that the trial is a failure - for instance the MARQUEE trial entrance criteria is closer to the MetMab ph ii entrance criteria in important ways than it is to the ARQL ph ii entrance criteria.

Should we assume this trial design was mandated by the FDA? Otherwise, why not pattern the Phase 3 after your Phase 2 and give yourself what would appear to be a greater chance for success in Phase 3?